SCHEMBL3011966

SCHEMBL3011966

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 9/20 0.34
MAPT P10636 3/20 0.33
HRH3 Q9Y5N1 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
RAB9A P51151 1/20 0.33
SCN1A P35498 1/20 0.33
SCN8A Q9UQD0 1/20 0.33
HTR2A P28223 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GBA1 P04062 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002167 0.93 MAPT (0.37) DNM1LMAPTSMN1; SMN2SCN1ASCN8A
SCHEMBL3017660 0.93 RAB9A (0.38) DNM1LMAPTSMN1; SMN2RAB9AHTR2A
SCHEMBL3003648 0.90 SMN1; SMN2 (0.38) DNM1LMAPTHRH3SMN1; SMN2RAB9A
SCHEMBL3011442 0.90 SCN1A (0.36) DNM1LMAPTSMN1; SMN2SCN1ASCN8A
SCHEMBL3014285 0.89 GBA1 (0.41) DNM1LMAPTHRH3SMN1; SMN2RAB9A
SCHEMBL3008395 0.89 SOS1 (0.37) DNM1LSMN1; SMN2SCN1ASCN8AHTR2A
SCHEMBL3016582 0.89 MAPT (0.40) MAPTHRH3SMN1; SMN2RAB9AHTR2A
SCHEMBL3009908 0.88 LMNA (0.38) MAPTHRH3SMN1; SMN2RAB9AHTR2A
SCHEMBL3006962 0.88 SMN1; SMN2 (0.35) DNM1LMAPTHRH3SMN1; SMN2RAB9A
SCHEMBL3021485 0.88 MAPT (0.35) DNM1LMAPTHRH3SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DNM1L 180/4885MAPT 18/4885HRH3 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.